Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus AMINOSYN HBC 7 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus AMINOSYN HBC 7 IN PLASTIC CONTAINER.
AMINOSYN 3.5% IN PLASTIC CONTAINER vs AMINOSYN-HBC 7% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair and growth in patients unable to tolerate oral/enteral nutrition.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Intravenous infusion of 500 mL to 1 L daily, providing 3.5% amino acids (31.5 g protein per liter). Administer at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic tolerance.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 18-24 minutes, reflecting rapid clearance from plasma into tissues for protein synthesis.
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
Amino acids are metabolized to urea and carbon dioxide; urea is excreted renally (90%) and to a lesser extent via sweat and feces (<10%).
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution